证券日报网讯 12月18日，优宁维（301166）在互动平台回答投资者提问时表示，公司将围绕一站式平 台极致战略和抗体极致战略，通过抗体上下游应用领域寻找相关标的企业，以实现与现有业务的协同发 展。同时通过开展股份回购计划，加强投资者沟通等方式维护公司股价平稳波动。后续公司将会继续运 用好股份回购、股权激励等工具，努力提升公司经营质量和业绩。 ...

Core Viewpoint - Huakai Yibai Technology Co., Ltd. has successfully completed its first share buyback, demonstrating confidence in its long-term development and aiming to enhance employee engagement through stock incentives [1][4]. Group 1: Buyback Announcement - On December 19, 2025, Huakai Yibai announced its first share buyback, completing the purchase of 1.2436 million shares, which represents 0.31% of the total share capital, with a total expenditure of 13.5926 million yuan (excluding transaction fees) [1][3]. - The buyback plan was approved during the fourth board meeting on December 17, 2025, with a budget of 15 million to 30 million yuan and a maximum buyback price of 17.35 yuan per share, to be executed within 12 months [2]. Group 2: Buyback Details - The first buyback operation took place on December 18, 2025, with the highest transaction price at 11.00 yuan per share and the lowest at 10.85 yuan per share, utilizing 13.5926 million yuan, which is 90.62% of the lower limit of the buyback plan [3]. - The buyback is intended for employee stock incentives and/or employee shareholding plans, aligning the interests of the core team with the company's long-term goals [4]. Group 3: Compliance and Future Plans - The buyback process adhered to the established plan and complied with relevant regulations, ensuring that the trading activities did not violate any price limits or trading rules [4]. - Huakai Yibai plans to continue the buyback within the 12-month period based on market conditions and will fulfill its information disclosure obligations as required [4].

券商资深人士指出，这一系列变化不仅是对监管的回应，更深层次反映了 证券行业从"重融 资"向"重回报"的价值转型， 致力于构建投资者与公司共赢的良性生态。 记者丨崔文静 编辑丨巫燕玲 12月19日，长城证券实施2025年中期派息，每手派发现金红利7.6元，合计派发现金红利约 3.07亿元。 这只是近期上市券商加大分红力度的一个缩影。在政策持续引导下，A股券商的分红实践在 2025年发生了重要变化，"一年多次分红"成为鲜明的新常态。 这场变化最直观的体现是分红频次的"井喷"。截至12月18日，叠加三季报分红与中报分红，全 年有35家券商分红达两次及以上，占比高达79.55%，意味着 近八成券商已进入"多次分红、及 时分享"的常态化阶段。 与此同时，分红的"含金量"在中报季尤为突出。头部券商引领风潮，中信证券2025中报每手分 红29元，中信建投、华泰证券、国泰海通等也力度可观。 从年度总额看， 中信证券、国泰海通等多家头部机构年内分红均超40亿元。 而近期推出的三 季报分红，则显示出行业在尝试提高分红频次上的新探索。 除了真金白银的分红，建立长期规划、探索"分红+回购"等多元化工具，正成为券商完善回报 体系的新方 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688557 证券简称：兰剑智能公告编号：2025-053 兰剑智能科技股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ■ 一、回购审批情况和回购方案内容 公司于2025年6月5日召开第五届董事会第八次会议，审议通过了《关于以集中竞价交易方式回购公司股 份方案的议案》，同意公司使用不低于人民币1000万元，不超过人民币2000万元的自有资金，以不超过 41.88元/股（含）的回购价格，回购公司股份并在未来适宜时机用于员工持股计划或股权激励，回购期 限为自董事会审议通过回购方案之日起12个月内。具体内容详见公司分别于2025年6月6日和2025年6月 13日在上海证券交易所网站（www.sse.com.cn）披露的《关于以集中竞价交易方式回购股份的预案》 （公告编号：2025-022）和《关于以集中竞价交易方式回购股份的回购报告书》（公告编号：2025- 024）。 二、回购实施情况 （一）公司于202 ...

关于回购A股股份事项前十名股东和前十名无限售条件股东持股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 中兴通讯股份有限公司(以下简称"公司")于2025年12月12日召开的第十届董事会第十七次会议审议通过 了《关于以集中竞价交易方式回购公司A股股份方案的议案》。有关本次回购A股股份事项具体情况详 见公司于2025年12月12日披露的《关于回购公司A股股份方案的公告暨回购报告书》。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第9 号一一回购股份》的相关 规定，现将公司董事会公告回购A股股份决议的前一个交易日（即2025年12月11日）登记在册的前十名 股东和前十名无限售条件股东的名称及持股数量、比例等情况公告如下： 一、公司前十名股东持股情况 ■ 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码（A/H）：000063/00763 证券简称（A/H）：中兴通讯公告编号：202570 中兴通讯股份有限公司 二、公司前十名无限售条件股东持股情况 ■ 注1：截至2025年12月11日，中兴新通讯有限公司合计持有公司股份96 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688331 证券简称：荣昌生物 公告编号：2025-056 荣昌生物制药（烟台）股份有限公司 关于回购股份事项前十名股东和 前十名无限售条件股东持股情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 荣昌生物制药（烟台）股份有限公司（以下简称"公司"）于2025年12月15日召开第二届董事会第三十二 次会议，审议通过了《关于以集中竞价交易方式回购公司股份方案的议案》，具体情况详见公司2025年 12月16日在上海证券交易所网站（www.sse.com.cn）披露的《荣昌生物关于以集中竞价交易方式回购股 份的预案》（公告编号：2025-055）。 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7号一一回购股份》等相关 规定，现将公司第二届董事会第三十二次会议决议公告的前一个交易日（即2025年12月15日）登记在册 的A股前十名股东和前十名无限售条件股东的名称、持股数量和比例情况公告如下： 一、董事会决议公告前一个交易日（2025年12 ...

New IPOs - The largest biotech IPO in Hong Kong for 2025 is initiated by Insilico Medicine (03696), which boasts the fastest global progress in AI drug development [1] - Lin Qingxuan (02657) will conduct its IPO from December 18 to December 23, attracting cornerstone investors like Fidelity [1] - Woan Robotics (06600) is set to launch its IPO during the same period, with an expected listing date of December 30 [1] - Meilian Holdings (02671) and Wuyi Vision (06651) will also hold their IPOs from December 18 to December 23, both expected to list on December 30 [1] - Xun Ce (03317) will follow the same IPO schedule, with a listing anticipated on December 30 [1] - Zhihui Mining (02546) achieved a remarkable 5248.15 times subscription in its public offering, with a listing date of December 19 [1] - China National Airlines (00753) plans to invest in Shenzhen Airlines' equity financing, with Kunhang Investment, a state-owned entity, being shortlisted [1] - Sensetime-W (00020) intends to place 1.75 billion new Class B shares, aiming to raise approximately HKD 3.146 billion [1] - Fosun Pharma (02196) is enhancing its overseas innovative drug strategy by signing a cooperation and option agreement with Clavis Bio [1] - WuXi AppTec (02359) invested around EUR 30 million to acquire a 3.22% stake in a French biopharmaceutical fund [1] - Minhua Holdings (01999) plans to acquire 100% equity in the American soft furniture company Gainline Recline Intermediate Corp [1] Share Buybacks - Tencent Holdings (00700) repurchased 1.055 million shares for HKD 636 million on December 18 [2] - Xiaomi Group-W (01810) spent HKD 151 million to buy back 3.75 million shares on the same day [2] - COSCO Shipping Holdings (01919) repurchased 5.9 million shares for HKD 80.557 million [2] - Country Garden Services (06098) bought back 2.7 million shares for HKD 17.136 million [2] - Jiangsu Ninghu Expressway (00177) saw an increase of 52.862 million shares by Yunsong Capital [2]

Group 1 - The core viewpoint of the news is that Sipai Health has been actively repurchasing its shares, indicating management's confidence in the company's stock value and financial health [1][2] - On December 18, Sipai Health repurchased 150,800 shares at an average price of 2.38 HKD per share, totaling approximately 359,500 HKD, bringing the total shares repurchased this year to 14,713,800, which accounts for 1.95% of the total share capital [1] - The recent share buyback is seen as a strategy to enhance earnings per share and improve capital structure, potentially positively influencing market sentiment [1] Group 2 - Sipai Health, established in 2014, focuses on healthcare services, including oncology management, pharmaceutical supply chain, and health insurance services [2] - The company integrates medical resources through a digital platform, providing comprehensive solutions for patients, doctors, and healthcare institutions [2] - Despite recent business expansion efforts, Sipai Health faces challenges in profitability and growth sustainability due to increased industry competition and regulatory environment [2]

Group 1 - Haitai Flavor Industry plans to distribute cash dividends of no less than 80% of the net profit attributable to shareholders for the next three years (2025-2027) [2] - Haitai will implement a special dividend plan for 2025, distributing 3.0 yuan (including tax) for every 10 shares [2] Group 2 - Xusheng Group's controlling shareholder is planning a change in control, leading to a suspension of trading for the company's stock starting December 19, 2025 [3] Group 3 - Guandong Quantum's chairman, Lü Pin, has passed away, and the company expresses deep condolences [4] Group 4 - Former controlling shareholder of Guao Technology, Chen Chongjun, has been sentenced to six years in prison for manipulating the securities market, with a fine of 4 million yuan [5] - The company states that this judgment will not significantly impact its operations [5] Group 5 - Tianfeng Securities plans to extend a 4 billion yuan subordinated debt for one year and reduce the interest rate from 5% to 4% [6] Group 6 - Zhongwei Company is planning to acquire controlling stakes in Hangzhou Zhonggui Electronic Technology Co., Ltd., leading to a stock suspension starting December 19, 2025 [7] Group 7 - Shandong Highway intends to provision for a long-term equity investment impairment of approximately 690 million yuan related to Dongxing Securities, which will reduce the company's consolidated profit for 2025 by the same amount [8] Group 8 - HeFu China has experienced a significant stock price increase of 349.25% from October 28 to December 18, 2025, despite being in a loss position [9] - The company warns of risks related to high valuation and operational performance [9] Group 9 - Xizang Pharmaceutical plans to repurchase shares worth between 170 million and 200 million yuan, with a maximum repurchase price of 55 yuan per share [11] Group 10 - Junshi Biological's major shareholder, Shanghai Tanying, plans to reduce its stake by up to 2% through block trading [12] Group 11 - Dazhong Mining's major shareholders and executives plan to reduce their holdings by up to 1.44% due to personal financial needs [13] Group 12 - Ruicheng Environmental Protection's shareholder plans to reduce its stake by up to 3% [14] Group 13 - Allianz Vision's actual controller Xu Jin plans to reduce his stake by up to 0.9609% [15] Group 14 - Yidong Electronics' controlling shareholder's concerted action reduced their holdings by 1% from December 10 to December 17 [16] Group 15 - Ningbo Construction won a project bid worth 747 million yuan for infrastructure enhancement [18] Group 16 - Qinglong Pipe Industry signed a sales contract worth 55.27 million yuan for a water diversion project [19] Group 17 - Zhongfutong received a selection notice for a procurement project with estimated amounts of 411 million yuan and 162 million yuan [20] Group 18 - Shikong Technology won a bid for a smart cultural tourism integration project worth 141 million yuan [21]

截至2025年12月18日收盘，迈得医疗（688310）报收于14.78元，较前一交易日上涨0.48%，最新总市值 为24.57亿元。该股当日开盘14.77元，最高15.05元，最低14.65元，成交额达4234.62万元，换手率为 1.71%。 公司近日发布公告，披露了关于回购股份事项前十大股东和前十大无限售条件股东的持股情况。公告显 示，迈得医疗工业设备股份有限公司于2025年12月11日召开第五届董事会第八次会议，审议通过以集中 竞价交易方式回购公司股份的议案。本公告披露了董事会公告回购股份决议前一个交易日（2025年12月 12日）登记在册的前十大股东及前十大无限售条件股东的持股情况，包括股东名称、持股数量和持股比 例。公司前两大股东分别为林军华和陈万顺，持股比例分别为47.15%和14.89%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 《迈得医疗工业设备股份有限公司关于回购股份事项前十大股东和前十大无限售条件股东持股情 况的公告》 最新公告列表 ...